Edward Lee Carter։ Stroke Prevention Starts in the Emergency Department – but Doesn’t End There
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared Emergency Medicine News’s post on LinkedIn about a recent article by Baldwin, published in Emergency Medicine News, adding:
”One of the most important moments in stroke prevention may occur in the Emergency Department.
Atrial fibrillation is increasingly encountered during acute care encounters, but initiating anticoagulation is often only the beginning of the challenge.
In real-world practice, the long-term success of anticoagulation frequently depends on what happens after discharge:
- patient understanding
- renal function follow-up
- medication affordability/access
- transitions of care
- peri-procedural planning
- coordination between clinicians
Underdosing DOACs ‘for safety’ when criteria are not met is another important issue that deserves continued attention, as inappropriate dose reduction may reduce efficacy without meaningfully improving outcomes.
Anticoagulation management is rarely just about selecting a drug.
It is about building a safe, understandable, sustainable plan for the patient.
That is where interdisciplinary care—including physicians, pharmacists, nurses, and patients themselves—can make a tremendous difference.”
Quoting Emergency Medicine News’s post:
”Atrial fibrillation is rising in the ED and early anticoagulation is one of the most impactful ways to prevent stroke. Current guidelines emphasize CHA₂DS₂‑VASc–based decisions, DOACs over warfarin, and correcting bleeding risks rather than withholding therapy.
Avoid underdosing (it raises stroke risk nearly 5 times), ensure patients understand their regimen, and remember: all cardioversion patients need at least 4 weeks of anticoagulation, regardless of method or timing.
ED clinicians are uniquely positioned to start stroke prevention at the moment it matters most.”
Title: Anticoagulation Strategies for Stroke Prevention in Atrial Fibrillation
Authors: Baldwin, Kendall PharmD Candidate, Hile, Kaitlin PharmD, BCCP, Hile, Garrett PharmD, BCEMP, BCCCP, Howington, Gavin T. PharmD, BCCCP, BCEMP

Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy